Company Profile · Healthcare

Fortrea Holdings Inc.

FTRE · US
Exchange
US
Country
USA
IPO date
Jul 3, 2023
Employees
14,000
Current Price
$15.31
Live · Jun 18, 2026
Fair Buy
≤ $10
Margin-of-safety entry
Baillie Growth Score
38/100
Weak
Intrinsic Value · Three-Tier Range Current price $15.31 Live · Within the fair intrinsic-value range

Composite valuation range · conservative $8–$10 / fair $15–$19 / optimistic $24–$28. At $15.31, Within the fair intrinsic-value range.

At publication $16.87 (Jun 12, 2026)

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Market cap$1.45B
Revenue (TTM)$2.71B
EBITDA$69.9M
Profit margin-16.5%
ROE-64.55%
Forward P/E11.96
PEG0.34
EPS-$4.81
52-week range$4.36 – $18.67
Analyst target$16.21
Analyst rating3.0 / 5

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.